TITLE

Viadur to be discontinued

PUB. DATE
February 2008
SOURCE
Pharmaceutical Representative;Feb2008, Vol. 38 Issue 2, p12
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that pharmaceutical company Bayer HealthCare Pharmaceuticals is planning to stop selling and marketing its Viadur (leuprolide acetate implant), a product intended for the management of symptoms associated with advanced prostate cancer in the U.S. According to the company, the decision was not influenced by any safety or efficacy issues of the product instead by the drug's limited long-term market viability.
ACCESSION #
28816893

 

Related Articles

  • AHCPR: LHRH agonists are equally effective.  // Urology Times;Mar99, Vol. 27 Issue 3, p3 

    Cites an Agency for Health Policy Research report which said that luteinizing hormone-releasing agonists produce roughly the same survival and side effects in men with advanced prostate cancer, regardless of which of the testosterone-suppressing drugs is taken.

  • Antithrombin III concentration, thrombosis, and treatment with luteinising hormone releasing hormone agonist in prostatic carcinoma. Varenhorst, E.; Svensson, M.; Hjertberg, H.; Malmqvist, E. // British Medical Journal (Clinical Research Edition);4/5/1986, Vol. 292 Issue 6525, p935 

    Investigates the effects of luteinising hormone releasing hormone agonist used in treating prostatic carcinoma. Observation on the fall in plasma antithrombin III concentration; Measurement of plasma antithrombin concentration before and during treatment; Estimation on the risk of...

  • Urologists may be targeted in second LHRH case.  // Urology Times;Aug2003, Vol. 31 Issue 8, p1 

    Reports that the federal government will pursue urologists in a second round investigations surrounding the fraudulent marketing and sale of luteinizing hormone-releasing hormone agonists for prostate cancer in the U.S. Details on the illegal billing of samples of goserelin acetate implant;...

  • Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer. Ishizuka, Osamu; Nishizawa, Osamu; Nishizawa, Shuji; Satoh, Tomoya; Wajiki, Masahisa; Kiyokawa, Hideo; Inoue, Yoshihiro; Kobayashi, Shinya; Mizusawa, Hiroya; Nakagawa, Tatsuo // International Journal of Clinical Oncology;Jun2013, Vol. 18 Issue 3, p524 

    Background: We compared the efficacy and safety of 1- and 3-month depots of the luteinizing hormone-releasing hormone (LH-RH) agonist goserelin acetate in prostate cancer patients. Methods: Patients were randomly assigned to the Direct Group that received the goserelin 3-month depot or the...

  • Medicare Reimbursement and Prescribing Hormone Therapy for Prostate Cancer. Keating, Nancy L. // JNCI: Journal of the National Cancer Institute;Dec2010, Vol. 102 Issue 24, p1814 

    The author ponders on the findings of a study on the use of gonadotropin-releasing hormone (GnRH) agonists for prostate cancer treatment, by Elliott and colleagues, published within the issue. The study assessed if the decreased reimbursements to providers resulting from the Medicare...

  • GnRH agonists confer increased risk of fractures. Lorio, Angela // Urology Times;10/1/2004, Vol. 32 Issue 14, p20 

    Examines the link of fracture with the administration of gonadotropin-releasing hormone (GnRH)agonists in men. Changes in the standard of care for hormone-refractory prostate cancer; Magnitude of risk observed with GnRH agonists; Percentage of the incidence rate of fracture.

  • Reimbursement cuts: Urologists prepare for the worst.  // Urology Times;10/1/2004, Vol. 32 Issue 14, p32 

    Focuses on the reduced reimbursement for luteinizing hormone-releasing hormone agonists for prostate cancer in the U.S. Access of cancer patients to treatment; Steps to cope with the loss of income; Percentage of Medicare and Medicaid coverage to patients.

  • Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer. Smith, Matthew R.; McGovern, Francis J.; Zietman, Anthony L.; Fallon, Mary Anne; Hayden, Douglas L.; Schoenfeld, David A.; Kantoff, Philip W.; Finkelstein, Joel S. // New England Journal of Medicine;9/27/2001, Vol. 345 Issue 13, p948 

    Background: Treatment with a gonadotropin-releasing hormone agonist decreases bone mineral density and increases the risk of fracture in men with prostate cancer. We conducted a controlled study of the prevention of osteoporosis in men undergoing treatment with a gonadotropin-releasing hormone...

  • Antiandrogen plus LHRHa efficacious in advanced PCa. Nierengarten, Mary Beth // Urology Times;9/1/2005, Vol. 33 Issue 11, p10 

    Reports on the therapeutic benefits of adding the nonsteroidal antiandrogen bicalutamide (Casodex) to a luteinizing hormone-releasing hormone agonist (LHRHa) in treating advanced prostate cancer (PCa) by researchers from Japan. Indications showing the effectiveness of maximal androgen blockade...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics